Recent Updates
Recently added Catalysts

ST-246

Phase 2

Orthopoxviral Disease | Small molecule | Infectious Disease |SIGA Technologies Inc.|Last Updated: Jul 27, 2017

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials1
Total Enrollment107
FDA Designations
No designations recorded
Clinical trial landscape

ST-246 · 2 trials · 2 indications

Phase 2 1Phase 1 1
NCT00907803Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246Orthopoxviral Disease
COMPLETED107 Analytics
PHASE2COMPLETED
Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246
Orthopoxviral DiseaseUnlock trial analytics
Study Endpoints
Primary Endpoints
Number of Study Participants Who Tolerated a Single Daily Oral ST-246 Dose as Determined by Safety Parameter Changes According to the DAIDS (Division of Acquired Immunodeficiency Syndrome) Adverse Events (AE) Grading Table.
Days 1 to 14; then 24, 48, 72, 96 and 120 hours and 4 weeks after final dose

Subjects were administered a single, daily oral dose of ST-246 (400 or 600 mg)and changes in safety parameteres were monitored. Safety parameters included adverse events, vital signs, physical examinations, laboratory tests (hematology, blood chemistry, and urinalysis) and electrocardiograms. The DAIDS AE grading table is a list of common terms and severity (intensity) of parameters used to describe adverse events occurring in NIAID-sponsored clinical studies/trials.

Number of Study Participants Who Tolerated ST-246 (250, 400 or 800mg) as Determined by Changes in Safety Parameters, According to the Division of Acquired Immunodeficiency Syndrome (DAIDS) Adverse Events (AE) Grading Table
Days 1, 6, 14-16, 21-24, 28-31, and 51-53

Evaluated safety parameters included: 1. physical examination/vital signs 2. electrocardiograms (heart rate, PR interval, QRS duration, QT interval, and QTc Bazett) 3. laboratory safety tests (hematology, chemistry, urinalysis) 4. adverse events (AEs) For a)-c), statistical values (mean, standard deviation, median, minimum, maximum) and changes from baseline (Day 1 pre-dose) to each time-point, were compared to laboratory normal reference ranges. If values for a)-d) were a Grade 3 or higher (in DAIDS AE Table)and ST-246-related, they were considered severe and significant, respectively.

Secondary Endpoints
Evaluation of Pharmacokinetic Parameters to Assess Interventions: Cmax
Day 1 post-dose
Evaluation of Pharmacokinetic Parameters to Assess Interventions: Tmax
Day 1 post-dose
Evaluation of Pharmacokinetic Parameters to Assess Interventions: AUCtau
Day 1 post-dose
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
Treatment Arms
ArmTypeDescription
ST-246 400 mgEXPERIMENTALST-246 400mg (2 x 200 mg Capsules) Orally Once Daily for 14 days
ST-246 600 mgEXPERIMENTALST-246 600 mg (3 x 200 mg Capsules) Orally Once Daily for 14 days
PlaceboPLACEBO_COMPARATORMatching Placebo capsules, Orally Once Daily for 14 days
ST-246EXPERIMENTAL250 mg, 400 mg or 800 mg of ST-246 given once daily for 21 days
Interventions
NameTypeDescription
ST-246 400 mgDRUGCapsules, 400 mg daily for 14 days
ST-246 600 mgDRUGCapsules, 600 mg daily for 14 days
PlaceboDRUGCapsules, once daily for 14 days
ST-246DRUG250 mg, 400 mg or 800 mg capsules given once daily for 21 days
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to 75 Years
SexALL
Healthy VolunteersYes
Study Sites3

Inclusion Criteria: 1. 18 - 75 yrs 2. Healthy volunteer 3. Ability to consent 4. Available for clinical follow-up for study 5. Not taking other medications 6. Adequate venous access 7. Using adequate birth control; negative pregnancy test 8. Able and willing to avoid alcohol for screening and study...

Countries:United States
Unlock Eligibility Criteria